An evaluation of a chemical cautery agent and an anti-inflammatory ointment for the treatment of recurrent aphthous stomatitis

A pilot study

Nelson L Rhodus, Janna Bereuter

Research output: Contribution to journalReview article

22 Citations (Scopus)

Abstract

Objective: Recurrent aphthous stomatitis is a very common condition, currently treated with anti-inflammatory agents, which palliate the symptoms. The purpose of this clinical trial was to compare a medication commonly used to treat recurrent aphthous stomatitis, Kenalog-in-Orabase, and a newer agent, Debacterol. Method and materials: Sixty patients diagnosed with recurrent aphthous stomatitis were enrolled in the study. Twenty patients were assigned to each of the two treatment groups, and 20 age- and sex-matched patients were assigned to the control group, which received no treatment. After the diagnosis was made, clinical examinations and ulcer measurements were performed, and a subjective evaluation of symptoms (100-mm visual analog scale) was completed by each subject. The subjects did not use any other medications. Both agents were applied topically (the frequency varied depending on the group of subjects) at specified intervals. Ulcer measurements and subjective evaluations were made at days 0, 3, 6, and 10 for all subjects. Results: In both treatment groups, by day 10, 100% of the ulcers had clinically healed and were no longer causing pain. Patients in the Debacterol group reported a significantly greater decrease in pain at 3 days (> 70%) than did subjects in the other groups (< 20%), although the size of the ulcer did not differ significantly in any of the groups. After day 6, 80% of the ulcers in the Debacterol group had clinically disappeared and no longer caused symptoms, as compared to about 30% in the other groups. Conclusion: Patients subjectively reported significantly greater relief from symptoms with Debacterol than with Kenalog-in-Orabase or no treatment. The relief of symptoms associated with recurrent aphthous stomatitis may or may not correspond to clinical improvement, and these two topical medications may affect signs and symptoms of the lesions differently.

Original languageEnglish (US)
Pages (from-to)769-773
Number of pages5
JournalQuintessence International
Volume29
Issue number12
StatePublished - Dec 1 1998

Fingerprint

Cautery
Ointments
Ulcer
Anti-Inflammatory Agents
Triamcinolone Acetonide
Therapeutics
Pain
Symptom Assessment
Visual Analog Scale
Signs and Symptoms
Age Groups
Sutton disease 2
Clinical Trials
Control Groups
sulfonated phenol drug combination sufuric acid

Keywords

  • Aphthous ulcer
  • Chemical cautery
  • Corticosteroid
  • Lesion
  • Recurrent aphthous stomatitis

Cite this

An evaluation of a chemical cautery agent and an anti-inflammatory ointment for the treatment of recurrent aphthous stomatitis : A pilot study. / Rhodus, Nelson L; Bereuter, Janna.

In: Quintessence International, Vol. 29, No. 12, 01.12.1998, p. 769-773.

Research output: Contribution to journalReview article

@article{3e83d73e5e034bc4b946172f982d11e6,
title = "An evaluation of a chemical cautery agent and an anti-inflammatory ointment for the treatment of recurrent aphthous stomatitis: A pilot study",
abstract = "Objective: Recurrent aphthous stomatitis is a very common condition, currently treated with anti-inflammatory agents, which palliate the symptoms. The purpose of this clinical trial was to compare a medication commonly used to treat recurrent aphthous stomatitis, Kenalog-in-Orabase, and a newer agent, Debacterol. Method and materials: Sixty patients diagnosed with recurrent aphthous stomatitis were enrolled in the study. Twenty patients were assigned to each of the two treatment groups, and 20 age- and sex-matched patients were assigned to the control group, which received no treatment. After the diagnosis was made, clinical examinations and ulcer measurements were performed, and a subjective evaluation of symptoms (100-mm visual analog scale) was completed by each subject. The subjects did not use any other medications. Both agents were applied topically (the frequency varied depending on the group of subjects) at specified intervals. Ulcer measurements and subjective evaluations were made at days 0, 3, 6, and 10 for all subjects. Results: In both treatment groups, by day 10, 100{\%} of the ulcers had clinically healed and were no longer causing pain. Patients in the Debacterol group reported a significantly greater decrease in pain at 3 days (> 70{\%}) than did subjects in the other groups (< 20{\%}), although the size of the ulcer did not differ significantly in any of the groups. After day 6, 80{\%} of the ulcers in the Debacterol group had clinically disappeared and no longer caused symptoms, as compared to about 30{\%} in the other groups. Conclusion: Patients subjectively reported significantly greater relief from symptoms with Debacterol than with Kenalog-in-Orabase or no treatment. The relief of symptoms associated with recurrent aphthous stomatitis may or may not correspond to clinical improvement, and these two topical medications may affect signs and symptoms of the lesions differently.",
keywords = "Aphthous ulcer, Chemical cautery, Corticosteroid, Lesion, Recurrent aphthous stomatitis",
author = "Rhodus, {Nelson L} and Janna Bereuter",
year = "1998",
month = "12",
day = "1",
language = "English (US)",
volume = "29",
pages = "769--773",
journal = "Quintessence international (Berlin, Germany : 1985)",
issn = "0033-6572",
publisher = "Quintessence Publishing Company",
number = "12",

}

TY - JOUR

T1 - An evaluation of a chemical cautery agent and an anti-inflammatory ointment for the treatment of recurrent aphthous stomatitis

T2 - A pilot study

AU - Rhodus, Nelson L

AU - Bereuter, Janna

PY - 1998/12/1

Y1 - 1998/12/1

N2 - Objective: Recurrent aphthous stomatitis is a very common condition, currently treated with anti-inflammatory agents, which palliate the symptoms. The purpose of this clinical trial was to compare a medication commonly used to treat recurrent aphthous stomatitis, Kenalog-in-Orabase, and a newer agent, Debacterol. Method and materials: Sixty patients diagnosed with recurrent aphthous stomatitis were enrolled in the study. Twenty patients were assigned to each of the two treatment groups, and 20 age- and sex-matched patients were assigned to the control group, which received no treatment. After the diagnosis was made, clinical examinations and ulcer measurements were performed, and a subjective evaluation of symptoms (100-mm visual analog scale) was completed by each subject. The subjects did not use any other medications. Both agents were applied topically (the frequency varied depending on the group of subjects) at specified intervals. Ulcer measurements and subjective evaluations were made at days 0, 3, 6, and 10 for all subjects. Results: In both treatment groups, by day 10, 100% of the ulcers had clinically healed and were no longer causing pain. Patients in the Debacterol group reported a significantly greater decrease in pain at 3 days (> 70%) than did subjects in the other groups (< 20%), although the size of the ulcer did not differ significantly in any of the groups. After day 6, 80% of the ulcers in the Debacterol group had clinically disappeared and no longer caused symptoms, as compared to about 30% in the other groups. Conclusion: Patients subjectively reported significantly greater relief from symptoms with Debacterol than with Kenalog-in-Orabase or no treatment. The relief of symptoms associated with recurrent aphthous stomatitis may or may not correspond to clinical improvement, and these two topical medications may affect signs and symptoms of the lesions differently.

AB - Objective: Recurrent aphthous stomatitis is a very common condition, currently treated with anti-inflammatory agents, which palliate the symptoms. The purpose of this clinical trial was to compare a medication commonly used to treat recurrent aphthous stomatitis, Kenalog-in-Orabase, and a newer agent, Debacterol. Method and materials: Sixty patients diagnosed with recurrent aphthous stomatitis were enrolled in the study. Twenty patients were assigned to each of the two treatment groups, and 20 age- and sex-matched patients were assigned to the control group, which received no treatment. After the diagnosis was made, clinical examinations and ulcer measurements were performed, and a subjective evaluation of symptoms (100-mm visual analog scale) was completed by each subject. The subjects did not use any other medications. Both agents were applied topically (the frequency varied depending on the group of subjects) at specified intervals. Ulcer measurements and subjective evaluations were made at days 0, 3, 6, and 10 for all subjects. Results: In both treatment groups, by day 10, 100% of the ulcers had clinically healed and were no longer causing pain. Patients in the Debacterol group reported a significantly greater decrease in pain at 3 days (> 70%) than did subjects in the other groups (< 20%), although the size of the ulcer did not differ significantly in any of the groups. After day 6, 80% of the ulcers in the Debacterol group had clinically disappeared and no longer caused symptoms, as compared to about 30% in the other groups. Conclusion: Patients subjectively reported significantly greater relief from symptoms with Debacterol than with Kenalog-in-Orabase or no treatment. The relief of symptoms associated with recurrent aphthous stomatitis may or may not correspond to clinical improvement, and these two topical medications may affect signs and symptoms of the lesions differently.

KW - Aphthous ulcer

KW - Chemical cautery

KW - Corticosteroid

KW - Lesion

KW - Recurrent aphthous stomatitis

UR - http://www.scopus.com/inward/record.url?scp=0032234906&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032234906&partnerID=8YFLogxK

M3 - Review article

VL - 29

SP - 769

EP - 773

JO - Quintessence international (Berlin, Germany : 1985)

JF - Quintessence international (Berlin, Germany : 1985)

SN - 0033-6572

IS - 12

ER -